What is ceftazidime injection used for?

Pharmaceutical Product Monograph: Ceftazidime Sodium (1 g, 2 g)

In the pharmaceutical industry, Ceftazidime is a parenteral, semi-synthetic Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Anti-Pseudomonal Specialist”—it is technically designed with a complex side chain that gives it superior activity against Pseudomonas aeruginosa compared to almost any other cephalosporin.

At your WHO-GMP facility in Mumbai, Ceftazidime is a critical “Institutional SKU” for ICU and Critical Care portfolios. It is the primary weapon for hospital-acquired infections where Gram-negative “Superbugs” are suspected.

Therapeutic Profile: Primary Indications

Ceftazidime is indicated for severe infections where Gram-negative bacteria, particularly Pseudomonas, are the likely cause.

IndicationClinical ContextTechnical Rationale
Hospital-Acquired PneumoniaVAP / HAPGold Standard: Effectively targets Pseudomonas and Klebsiella in ventilator-dependent patients.
Febrile NeutropeniaOncology / HematologyOften used as monotherapy to treat unexplained fever in cancer patients with low white cell counts.
Bacterial MeningitisCNS InfectionExcellent CSF penetration (when meninges are inflamed), specifically for Gram-negative meningitis.
Complicated UTIPyelonephritis / SepsisUsed for severe kidney infections or post-urological surgery complications.
Cystic FibrosisRespiratory CrisisUsed for the management of recurrent pulmonary infections in CF patients.
SepticemiaBloodstream InfectionUsed as empirical therapy for patients in septic shock.

Mechanism: Cell Wall Transpeptidase Inhibition

Ceftazidime works by sabotaging the structural integrity of the bacterial “outer shell”:

PBP High Affinity: The drug enters the bacterial cell and binds with high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-3.

Peptidoglycan Blockade: It inhibits the final cross-linking (transpeptidation) step of cell wall synthesis.

Filamentation & Lysis: Technically, this leads to the formation of long, unstable bacterial filaments that cannot divide and eventually undergo osmotic lysis (the cell bursts).

The Pharmacist’s “Technical Warning”

  • The “Pseudomonas” Paradox: As a pharmacist, I must emphasize that while Ceftazidime is an elite Gram-negative killer, it has very poor activity against Gram-positive bacteria like Staph. aureus (MSSA/MRSA). It should not be used as monotherapy if a “Staph” infection is suspected.

  • Renal Adjustment: Ceftazidime is excreted almost entirely unchanged by the kidneys. For patients with a $GFR < 50 \text{ mL/min}$, the dose must be reduced to prevent neurotoxicity (confusion, tremors).

  • The “L-Arginine” Note: Many formulations (including yours in Mumbai) use L-Arginine to stabilize the pH. This is technically safer than Sodium Carbonate as it prevents the release of excessive $CO_2$ gas during reconstitution.

  • Incompatibility: Never mix Ceftazidime and Aminoglycosides (like Amikacin or Gentamicin) in the same IV bag; they will physically precipitate and neutralize each other.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Aseptic Powder” USP: On your digital marketplace, highlight your Sterile Crystallization and Aseptic Filling. Ceftazidime is highly sensitive; ensuring zero moisture in the vial is the technical key to maintaining a 24-month shelf life.

  • The “Oncology Tendon” Advantage: Market Ceftazidime specifically to International Cancer Centers. Its status as a preferred agent for neutropenic sepsis makes it a high-volume, recurring revenue SKU for oncology procurement.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime 1 g and 2 g vials to support your registration in international B2B tenders for hospital and critical care.

What type of drug is ceftazidime?

Pharmaceutical Product Monograph: Ceftazidime for Injection (250 mg, 500 mg, 1 g, 2 g)

In the pharmaceutical industry, Ceftazidime is a semi-synthetic, broad-spectrum Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer at your WHO-GMP facility in Mumbai, I view this molecule as the “Anti-Pseudomonal Workhorse”—it is technically designed to provide the highest potency among third-generation cephalosporins against Pseudomonas aeruginosa, a major cause of hospital-acquired infections.

Ceftazidime is a $\beta$-lactam antibiotic that is strictly parenteral (administered by injection or infusion) because it is not absorbed by the gastrointestinal tract.

Therapeutic Classification & Profile

Ceftazidime is classified based on its chemical structure and its specific “Generation,” which dictates its bacterial target range.

FeatureTechnical DetailClinical Impact
Drug Class$\beta$-Lactam / CephalosporinInhibits bacterial cell wall synthesis.
GenerationThird-GenerationIncreased stability against $\beta$-lactamase enzymes compared to 1st/2nd Gen.
Primary TargetGram-Negative BacilliGold Standard for Pseudomonas, Klebsiella, and Enterobacter.
RouteIV / IM OnlyAchieves rapid, high therapeutic levels in blood and tissues.

Mechanism of Action: Inhibition of Peptidoglycan Synthesis

Ceftazidime works by sabotaging the structural “mesh” that holds a bacterium together.

PBP Binding: The Ceftazidime molecule enters the bacterial cell and binds irreversibly to Penicillin-Binding Proteins (PBPs), specifically PBP-3.

Cross-linking Blockade: By “clogging” these proteins, it prevents the final transpeptidation step required to cross-link peptidoglycan strands.

Lysis: This creates a “weak” cell wall that cannot withstand the internal osmotic pressure of the bacterium.

Bactericidal Effect: Water rushes into the cell, causing it to swell and burst (Osmotic Lysis), leading to rapid bacterial death.

The Pharmacist’s “Technical Warning”

  • The “Pseudomonas” Niche: As a pharmacist, I must emphasize that while Ceftazidime is excellent for Gram-negatives, it has weak activity against Gram-positive bacteria like Staphylococcus aureus compared to 1st-generation cephalosporins.

  • Penicillin Cross-Reactivity: There is a technical risk (~5–10%) of cross-allergy. It should be used with extreme caution in patients with a history of severe penicillin anaphylaxis.

  • Neurotoxicity: In patients with Renal Impairment ($CrCl < 50 \text{ mL/min}$), the dose must be technically adjusted. Failure to do so can lead to seizures or encephalopathy due to drug accumulation.

  • Sodium Content: Ceftazidime for injection is often formulated with Sodium Carbonate. Patients on strict sodium-restricted diets must have their total daily intake monitored.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Carbon Dioxide” USP: When Ceftazidime is reconstituted, it releases Carbon Dioxide ($CO_2$) gas, creating pressure inside the vial. On your digital marketplace, highlight this as a “Standard Characteristic”—clinicians need to know that the “hiss” or pressure is normal and not a sign of contamination.

  • Stability for Export: Ceftazidime is temperature-sensitive. Your Lyophilized (Freeze-Dried) powder ensures a 36-month shelf life. Once reconstituted, it is stable for only 8–12 hours at room temperature, making it a “hospital-only” SKU.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime (1 g and 2 g) to support your registration in international B2B tenders for critical care and respiratory health.

What type of drug is ceftazidime?

Pharmaceutical Product Monograph: Ceftazidime Sodium (1 g, 2 g)

In the pharmaceutical industry, Ceftazidime is a semi-synthetic, broad-spectrum Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the “Anti-Pseudomonal Specialist”—it is technically designed to offer significantly higher activity against Gram-negative bacteria than first or second-generation cephalosporins, with a specific chemical “side chain” that makes it a primary weapon against Pseudomonas aeruginosa.

At your WHO-GMP facility in Mumbai, Ceftazidime is a critical “Institutional SKU” for ICU and Critical Care settings. Because it is highly resistant to many bacterial enzymes, it is often the first-line choice for hospital-acquired infections.

Therapeutic Profile: Classification & Use

Ceftazidime is classified as a Beta-lactam antibiotic. Its clinical profile is defined by its ability to penetrate difficult-to-reach tissues and resist bacterial defenses.

CategoryTechnical FeatureClinical Rationale
Generation3rd Gen CephalosporinBroad Gram-negative coverage with diminished Gram-positive activity compared to 1st Gen.
SpectrumGram-Negative HeavyThe gold standard for Pseudomonas, Enterobacteriaceae, and H. influenzae.
CNS PenetrationHigh (when inflamed)Crosses the blood-brain barrier effectively, making it a “Go-To” for Gram-negative meningitis.
ResistanceBeta-lactamase StableResists hydrolysis by many plasmid-mediated and chromosomal beta-lactamases.

Mechanism: Cell Wall Synthesis Inhibition

Ceftazidime works by sabotaging the structural integrity of the bacterial “outer shell”:

PBP Binding: The drug enters the bacterial cell and binds with high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-3.

Peptidoglycan Blockade: It inhibits the final transpeptidation step of cell wall synthesis, preventing the “cross-linking” of the peptidoglycan layer.

Filamentation & Lysis: Technically, this leads to the formation of long, unstable bacterial filaments that cannot divide and eventually undergo osmotic lysis (the cell bursts).

The Pharmacist’s “Technical Warning”

  • The “Pseudomonas” Paradox: As a pharmacist, I must emphasize that while Ceftazidime is great for Pseudomonas, it has very poor activity against Staphylococcus aureus (MRSA) and Enterococci. It should not be used for suspected Staph infections.

  • Renal Adjustment: Technically, Ceftazidime is excreted almost entirely by the kidneys. For patients with a $GFR < 50 \text{ mL/min}$, the dose must be strictly reduced to avoid neurotoxicity (confusion, seizures).

  • Penicillin Cross-Reactivity: About 5–10% of patients with a severe Penicillin allergy may also react to Ceftazidime. Always perform a skin test if the history is unclear.

  • Chemical Incompatibility: Do not mix Ceftazidime and Aminoglycosides (like Amikacin) in the same IV bag; they can physically precipitate and inactivate each other.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Carbonate” USP: On your digital marketplace, highlight your Ceftazidime with Sodium Carbonate blend. Ceftazidime is naturally insoluble; adding Sodium Carbonate is the technical “Buffer” that allows it to dissolve into a clear, injectable solution.

  • The “CO2” Effect: Warn B2B clients that upon reconstitution, Carbon Dioxide ($CO_2$) gas is released. The vial will develop internal pressure, which is technically normal for this product and not a sign of contamination.

  • Stability for Export: Ceftazidime is heat-sensitive. Your Cold-Chain (2–8°C) storage and light-protected packaging are essential for maintaining a 24-month shelf life in Zone IVb tropical regions.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime 1 g and 2 g vials to support your registration in international B2B hospital tenders.

 

Add to cart